tiprankstipranks
Trending News
More News >

Paradigm Biopharmaceuticals Reports Reduced Losses Amid Ongoing Osteoarthritis Treatment Development

Story Highlights
Paradigm Biopharmaceuticals Reports Reduced Losses Amid Ongoing Osteoarthritis Treatment Development

Don’t Miss TipRanks’ Half Year Sale

Paradigm Biopharmaceuticals Ltd. ( (AU:PAR) ) has issued an update.

Paradigm Biopharmaceuticals Ltd. reported a significant decrease in losses for the half-year ending December 2024, with a net loss of $5.92 million compared to $44.13 million in the previous period. This improvement is primarily due to reduced research and development costs following the conclusion of the PARA_OA_002 study, which was critical in determining the optimal dosing for their Phase 3 osteoarthritis treatment. Despite the reduced losses, the company anticipates continued financial challenges as it progresses with its clinical and regulatory efforts.

More about Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd. is a late-stage clinical development company focusing on advancing its lead Phase 3 asset, iPPS, for the treatment of osteoarthritis. The company is investing in clinical, regulatory, and commercial activities to support the development of iPPS, which has the potential to become a blockbuster treatment for osteoarthritis.

YTD Price Performance: 27.04%

Average Trading Volume: 8,346

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $133.9M

For an in-depth examination of PAR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1